HC Wainwright & Co. Maintains Neutral on NovoCure, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar maintains a Neutral rating on NovoCure (NASDAQ:NVCR) and raises the price target from $22 to $24.
July 26, 2024 | 9:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Emily Bodnar maintains a Neutral rating on NovoCure and raises the price target from $22 to $24.
The raised price target from $22 to $24 indicates a positive outlook, which could lead to a short-term increase in NVCR's stock price. However, the Neutral rating suggests limited upside potential.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100